A phase I trial found durvalumab in combination with dabrafenib (a BRAF inhibitor) and trametinib (a MEK inhibitor) to be feasible for the treatment of BRAF-mutant melanoma (25). This evidence concerns the gene MAP2K7 and melanoma.